🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Somatic mutations are changes to #DNA that accumulate in cells over our lifetime. At Quotient, we're using our platform to explore this vast genetic diversity inside us to identify new therapeutic opportunities. Learn more: bit.ly/3z6OQDW

Join us in welcoming Sir Mene Pangalos, PhD, to our Board of Directors! His extensive experience in R&D will be deeply valuable as we advance our #SomaticGenomics platform to develop first-in-class medicines for a wide range of diseases. Read more: bit.ly/3UGllkq

#SomaticGenomics has near limitless possibilities in driving transformative treatments across a multitude of therapeutic areas. Learn more about how we are using our platform to advance target identification and #DrugDevelopment: bit.ly/3UzKYTP

We’re honored to be named a 2024 BioTech Breakthrough winner for Biotech Startup of the Year! This recognition highlights our commitment to innovation as we use our #SomaticGenomic platform to pioneer novel therapies. View the list of winners here: bit.ly/4fq1IFr

Our Co-Founder and CEO, Jacob Rubens, recently joined Theral Timpson for an episode on the mendelspod podcast. Tune in as he highlights how our #SomaticGenomics platform is revolutionizing the #DrugDiscovery and development process. Listen here: bit.ly/4fXDsdy

Using the most accurate and sensitive sequencing technology, our #SomaticGenomics platform has the potential to identify links between genes and disease that are undetected by traditional approaches. For more on our platform's capabilities, visit: bit.ly/3AkWg71

Wishing a joyful holiday season from our team to yours! This year, we made strides in advancing our #SomaticGenomics platform for the discovery and development of transformative therapeutics, and we're excited to build on this momentum in 2025.

Our genomes are more dynamic & complex than we once thought. In this The Atlantic piece, Dr. Jason Liebowitz explores the multifaceted impact of #SomaticMutations on disease and includes insights from our CEO Jake Rubens on the immense genomic variation in our cells. Read more:

As we reflect on 2024, we’re proud of the strides we’ve made - from expanding our team, to advancing our #SomaticGenomics platform, and announcing two research programs in partnership with @Pfizer. We look forward to continued growth in 2025.

Polyintelligence: the fusion of human, machine & nature's intelligence. In Flagship Pioneering's annual letter, Founder & CEO Noubar Afeyan explores polyintelligence. See how we're pioneering a new frontier of human genetics in a case study featured here: flagshippioneering.com/polyintelligen…

Our CEO, Jacob Rubens, visited the Flagship Pioneering Studio at this year's J.P. Morgan conference to discuss how Quotient is using #SomaticGenomics to transform drug discovery and development, as well as highlight some recent progress from the company. #FlagshipJPM #JPM25

From pipeline developments and clinical milestones to new partnerships, hear from the CEOs and leaders of #FlagshipFounded companies advancing novel science and platforms to make #BiggerLeaps for human health. Watch all the conversations: flagshippioneering.com/topics/ceo-cha… 🔹 Lovisa

#ICYMI our Head of Platform, Simon Brunner, was featured in the latest Scrip, Citeline Commercial Asks issue discussing the role that AI and #SomaticGenomics play to uncover novel drug targets informed by the true complexity of human biology. Read more here: bit.ly/3PWQjBR

From the double helix to the Human Genome Project, UK & US teams have long shaped biology’s future. With UK #SomaticGenomics research & US biotech expertise, we're using genetics to transform medicine. Read more from Georgia Banjo in The Economist: bit.ly/4aIeKfU

In this MedNous article, our CEO, Jake Rubens, shares how advancements in #SomaticGenomic analysis are redefining our understanding of biology and driving the development of innovative therapies. Read more here: bit.ly/4hH793x

This International Day of #WomenAndGirlsInScience, we're celebrating the incredible women on our team whose passion and expertise drive innovation and inspire us daily as we pioneer the field of #SomaticGenomics. #WomenInSTEM

#ICYMI, our CEO, Jacob Rubens, spoke on one of Flagship Pioneering’s panels at #JPM25 about the power of platform technologies. Tune in as he discusses the development of our #SomaticGenomics platform & its potential impact on #DrugDiscovery and development: bit.ly/3WvxQjA

To celebrate #InternationalWomensDay, we're highlighting the incredible women on our team, like Kelly Becker, whose work as an Associate Scientist of Assay Development helps to advance our #SomaticGenomics platform. Learn about our values bit.ly/3WLvOei #WomenInSTEM

Our #SomaticGenomic platform not only identifies links between genes & disease but can also help us develop diverse therapeutic modalities—from small molecules to gene therapies & beyond. Learn how we’re uncovering new treatment possibilities: bit.ly/3UzKYTP

At Quotient, we’re proud to have such a talented team! Qin Wang brings her passion for collaboration to the team in her work as an Applied Statistical Geneticist focused on using #SomaticGenomic insights to identify priority drug targets for development. #QuotientVisionary